SetPoint Medical Starts Testing Unique Neuromodulation Device In Rheumatoid Arthritis Patients

SetPoint Medical announced the launch of a multicenter clinical trial to test its vagus nerve stimulation system in rheumatoid arthritis patients who did not adequately respond to multiple biologic agents. Among the company's backers are Medtronic, Boston Scientific and GSK.

film x-ray both human's hands and arthritis at multiple joint (Gout,Rheumatoid)

Valencia, California-based SetPoint Medical Corp. announced today it will enroll 15 rheumatoid arthritis (RA) patients in a study to assess the safety and effectiveness of its unique vagus nerve stimulation system. Patients must be ages 22-75 and have failed to adequately respond to multiple biologic agents.

The pilot trial builds on SetPoint's previously published results from a proof-of-concept study of 17 patients with active RA. In...

More from Neurology

More from Device Area